Sibelius Limited Announces Exclusive US Distribution Agreement with Barrington Nutritionals

Oxford, UK – Dec 14, 2017 – Sibelius Limited is pleased to announce that it has entered into an exclusive US distribution agreement with Barrington Nutritionals (Harrison, NY) for the sale of its ingredients and services into the US market. Peter Leyland, CEO of Sibelius Limited, states that Barrington Nutritionals’ strategic approach, industry reputation, and extensive resources made them a strong partner for Sibelius’ entry into the US nutraceuticals market.

Sibelius™:Sage is the first of several Sibelius’ pipeline products that are expected to be released to the nutraceutical market in the next few years. In a double-blind, placebo controlled RCT, the proprietary extract was shown to have significant effects on cognitive performance in healthy elderly volunteers in the areas of secondary memory and accuracy of attention. “Barrington Nutritionals is excited to lead the US launch of the first clinically validated Sibelius product, Sibelius: Sage™, a proven solution for cognition health”, states Stu Gelbard, President of Barrington Nutritionals.

About Barrington Nutritionals
Recognized for over 25 years for our commitment to quality, reliability and unparalleled customer service, Barrington’s diverse product portfolio serves the nutraceutical, pharmaceutical, and functional food industries. With our document database, responsive customer service, and fast shipping, we make it easy for our customers to formulate innovative and scientifically-backed products.

About Sibelius Ltd.
Sibelius Ltd. is a scientifically led company, based in Oxford, UK, that works with leading product researchers and developers to create, test and commercialize innovative and efficacious natural products. It works at the cutting edge, by offering unique insights into nutraceuticals that promote healthy ageing. Sibelius Ltd has an extensive database of natural products with known biological activity readout that has recently been made available for licensing and new product development.

Leave a Reply